The introduction of atracurium and vecuronium in the early 1980s was an important advance in the development of muscle relaxants for clinical use. These drugs have an intermediate duration of action, they lack cumulation to a certain extent and are easily reversible. They also in general terms provide good cardiovascular stability. However, even their introduction, although a vast improvement, did not fulfil some of the criteria for an ideal relaxant proposed by Savarese and Kitz (1). There are some reports of bradycardia with the use of both agents; atracurium may liberate histamine and both have a relatively slow onset of effect.
KeywordsPlasma Cholinesterase Rapid Sequence Induction Equipotent Dose Intermediate Duration Plasma Cholinesterase Activity
Unable to display preview. Download preview PDF.
- 8.Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RP, Sunder N, Weakly JN, Wastila WB, El-Sayad HA. The clinical neuromuscular pharmacology of mivacurium chloride (DW B 109U), a short acting norndepolarising ester neuromuscular blocking drug. Anesthesiology 1988; 68: 723–732.PubMedCrossRefGoogle Scholar
- 11.Connolly FM, Loan PB, McCoy EP, Mirakhur RK. Antagonism of mivacurium block with edrophonium from various degrees of spontaneous recovery. British Journal of Anaesthesia 1994; 73: 723P-724P.Google Scholar
- 13.Loan PB, Bhanamurthy S, Mirakhur RK, McCoy EP, McMurray TJ, Connolly FM. Haemodynamic effect of mivacurium under high dose fentanyl anaesthesia. Comparison with atracurium. British Journal of Anaesthesia 1994; 73: 715P.Google Scholar
- 30.Connolly FM, Mirakhur RK, Loan PB, McCoy E, Morrow BC. Time course of action of ORG 9487 with and without reversal: comparison with suxamethonium. British Journal of Anaesthesia 1995; in press.Google Scholar